Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.

被引：0
|
作者：
Ochenduszko, Sebastian
Garcia, Javier
Juan-Fita, Maria Jose
Gonzalez-Barrallo, Ines
Colomina, Julio Herrero
Beveridge, Robert Diaz
Martinez, Silverio Ros
Lafuente, Blanca Sanchez
Tomas, Alberto Jacobo Cunquero
Berrocal, Alfonso
Cerezuela-Fuentes, Pablo
Fra, Pablo Luna
Peeters, Alicia Gervas
Gonzalez, Jose Luis Sanchez
Garcia, Andres Meana
Garcia, Mariasun Algarra
Garcia, Eugenio Palomares
Altozano, Javier Perez
Guerola, Monica Tallon
Maestu, Inmaculada
机构：
[1] Hosp Univ Dr Peset, Valencia, Spain
[2] Hosp Ctr Tourcoing, Tourcoing, France
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Hosp Clin Univ Valencia, INCLIVA, Valencia, Spain
[5] Unidad Canc Gipuzkoa, OSID Onkol, San Sebastian, Spain
[6] Hosp Univ Politecn La Fe, Valencia, Spain
[7] Hosp Clin Univ Virgen Arrixaca, Murcia, Spain
[8] Hosp Gen Univ Valencia, Valencia, Spain
[9] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
[10] Hosp Univ Son Espases, Palma de Mallorca, Spain
[11] Hosp Univ Doctor Peset, Valencia, Spain
[12] Hosp Gen Univ Alicante, Alicante, Spain
[13] Hosp Marina Baixa, Villajoyosa, Spain
[14] Hosp Univ Vinalopo, Elche, Spain
[15] Hosp Virgen Los Lirios, Alcoy, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21529
引用
收藏
页数：1
相关论文
共 50 条
  • [31] CLINICAL ACTIVITY AND SAFETY OF ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Sosman, J.
    Sznol, M.
    McDermott, D. F.
    Carvajal, R.
    Lawrence, D. P.
    Topalian, S. L.
    Wigginton, J. M.
    Kollia, G.
    Gupta, A.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 361 - 361
  • [32] Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
    Ascierto, Paolo Antonio
    Lipson, Evan J.
    Dummer, Reinhard
    Larkin, James
    Long, Georgina V.
    Sanborn, Rachel E.
    Chiarion-Sileni, Vanna
    Dreno, Brigitte
    Dalle, Stephane
    Schadendorf, Dirk
    Callahan, Margaret K.
    Nyakas, Marta
    Atkinson, Victoria
    Gomez-Roca, Carlos Alberto
    Yamazaki, Naoya
    Tawbi, Hussein A.
    Sarkis, Naomey
    Warad, Deepti
    Dolfi, Sonia
    Mitra, Priyam
    Suryawanshi, Satyendra
    Grob, Jean-Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2724 - +
  • [33] NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]; BMS-936558) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: CLINICAL ACTIVITY, SAFETY, AND MOLECULAR MARKERS
    Feltquate, D. M.
    ANNALS OF ONCOLOGY, 2013, 24 : 7 - 7
  • [34] Anti-programmed death ligand 1 immunotherapy in patients with limited-stage small cell lung cancer: a real-world exploratory study
    Yao, Nan
    Qin, Zhaohui
    Ma, Ji
    Lu, Jiaying
    Sun, Kaiguo
    Zhang, Yiqing
    Qu, Wanxi
    Cui, Li
    Yuan, Shiwang
    Jiang, Aijun
    Li, Na
    Tong, Shaodong
    Yao, Yuanhu
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (05) : 448 - 454
  • [35] Smoking-Related Outcomes of Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1) Therapy: A Single Institution Study
    Hafiz, M.
    Naqash, A. R.
    Stroud, C. R. G.
    Bowling, M.
    Walker, P. R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1568 - S1569
  • [36] A PHASE II STUDY OF THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTIBODY PENPULIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL)
    Song, Yuqin
    Zhou, Keshu
    Jin, Chuan
    Qian, Zhengzi
    Hou, Ming
    Fan, Lei
    Li, Fei
    Ding, Kaiyang
    Zhou, Hui
    Li, Xiaoling
    Chen, Bing
    Sun, Xiuhua
    Song, Xianmin
    Jiang, Ming
    Zhang, Qingyuan
    Liu, Lihong
    Yu, Guohua
    Hu, Yu
    Zhao, Zheng
    Liu, Ligen
    Xue, Hongwei
    Luo, Jun
    He, Bai
    Jin, Xiaoping
    Wang, Maxwell
    Li, Baiyong
    Xia, Yu
    Zhu, Jun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A473 - A474
  • [37] Real-world experience with anti-programmed cell death protein 1 immunotherapy in patients with esophageal cancer: A retrospective single-center study
    Wang, Xinpeng
    Cai, Lvjuan
    Wu, Mengjing
    Li, Guo
    Zhu, Yunyun
    Lin, Xinyue
    Yan, Xue
    Mo, Peng
    Luo, Huachun
    Fu, Zhichao
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
    Liu, Qingyan
    Li, Rong
    Li, Lingling
    Wang, Gaokun
    Ji, Shiyu
    Zheng, Xuan
    Jia, Xiaodong
    Tao, Haitao
    Hu, Yi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [39] Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study
    Dousset, Lea
    Pacaud, Alize
    Barnetche, Thomas
    Kostine, Marie
    Dutriaux, Caroline
    Pham-Ledard, Anne
    Beylot-Barry, Marie
    Gerard, Emilie
    Prey, Sorilla
    Andreu, Nicolas
    Boniface, Katia
    Seneschal, Julien
    JAAD INTERNATIONAL, 2021, 5 : 112 - 120
  • [40] A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy
    Li, Su-Chen
    Deng, Shen -Wen
    Sun, Xue-Song
    Lan, Kai-Qi
    Guo, Chun-Yan
    Lin, Da-Feng
    Liu, Li-Ting
    Liu, Sai-Lan
    Mai, Hai-Qiang
    Tang, Lin-Quan
    ORAL ONCOLOGY, 2023, 139
12345